Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
4.250
+0.030 (0.71%)
At close: Feb 12, 2026, 4:00 PM EST
4.240
-0.010 (-0.24%)
After-hours: Feb 12, 2026, 4:10 PM EST
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change
5
Growth
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,411,999
Market Cap
98.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Seer, Inc. | 134 |
| Artiva Biotherapeutics | 106 |
| Biomea Fusion | 42 |
| Vivani Medical | 37 |
| Cassava Sciences | 30 |
| Cognition Therapeutics | 28 |
| Oncolytics Biotech | 28 |
ACTU News
- 4 weeks ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 5 weeks ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 6 months ago - Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - GlobeNewsWire
- 7 months ago - Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - GlobeNewsWire